Editas, BMS extend T cell deal; KalVista seeks partner for preclinical HAE program

Plus, news about Novo Holdings, Pepper Bio, G1 Therapeutics and Akari:

Editas, Bristol Myers Squibb add two years to T cell pact: The companies are extending a research deal for gene-edited alpha-beta T cell therapies into 2026. The deal includes both cancer and autoimmune diseases. Bristol Myers has opted into 13 different programs to date, with two in preclinical studies that could be used to apply for clinical trials. Financial terms of the deal were not disclosed. — Lei Lei Wu

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Readers respond to essays on long Covid, hypochondria, and more

First Opinion is STAT’s platform for interesting, illuminating, and maybe even provocative articles about the life sciences writ large, written by biotech insiders, health care

June 22, 2024

Racial and socioeconomic integration linked to lower health care expenditure disparities

Differences in health care expenditures between Black and white adults vary substantially with the local level of racial and economic integration, and tend to be

November 3, 2023

Opinion | Diversity Action Plans for Clinical Trials: Evaluating FDA’s Draft Guidance

Lazarus is an adjunct professor of psychiatry. Jernigan is chief operating officer of a service provider for participants in clinical trials. The FDA is intent

September 7, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.